Morán E, Rogel R, Soto A, Ruiz-Cerdá J L, Budía A, Salom J V, Jiménez-Cruz J F
Servicio de Urología, Hospital Universitario y Politécnico La Fe, Valencia, España.
Actas Urol Esp. 2012 Jun;36(6):352-8. doi: 10.1016/j.acuro.2011.11.006. Epub 2012 Jan 21.
To evaluate if re-grading renal cell carcinoma (CRCC) in two or three-tiered grading schemes versus the traditional Fuhrman classification maintains the same prognostic value.
A study of a cohort of 383 treated CRCC with radical or partial nephrectomy between 1990-2009 was made. We analyzed the demographic data, evolution and survival of these patients. An uropathologist reassigned the Fuhrman grades blindly to the first classification. In order to study if the prognostic value was maintained with the different classification, three Cox multivariate regression analysis were performed, classifying the variable of grade into four categories: (I-II-III-IV), into three (I+II-III-IV) and into two (I+II-III+IV). The explanatory variables were: age, gender, tumor size, study stage and grade. The response variables were progression-free survival (local-regional recurrence/metastasis) and cancer specific survival time.
The median overall survival was 125 months (95% CI: 92-159). In the three multivariate analyses carried out, the Fuhrman classification showed independent predictive value (p=:0.0001) compared to progression-free survival and cancer specific survival. The predictive power was maintained in the new classifications. In the three categories, the changing from grade I+II to III meant RR: 2.31 (p=0.0001) and from grade III to IV RR: 2.47 (p=0.0001) and in two-tiered classification an RR: 2.8 (p=0.001) was found when changing from I+II to III+IV.
Our results show that categorizing the Fuhrman grade into three or two-tiered grading schemes provide the same predictive accuracy on progressive free survival and cancer specific survival. Grades III and IV have different outcomes so that the three-tiered classification seems to be more appropriate to described the course of these patients.
评估在两分级或三分级方案中对肾细胞癌(CRCC)重新分级与传统的富尔曼分类法相比是否具有相同的预后价值。
对1990年至2009年间接受根治性或部分肾切除术治疗的383例CRCC患者进行队列研究。我们分析了这些患者的人口统计学数据、病情发展和生存情况。一名泌尿病理学家对首次分类的富尔曼分级进行了盲法重新评定。为了研究不同分类法是否保持预后价值,进行了三次Cox多因素回归分析,将分级变量分为四类(I-II-III-IV)、三类(I+II-III-IV)和两类(I+II-III+IV)。解释变量为:年龄、性别、肿瘤大小、研究分期和分级。反应变量为无进展生存期(局部区域复发/转移)和癌症特异性生存时间。
总生存期的中位数为125个月(95%可信区间:92-159)。在进行的三次多因素分析中,与无进展生存期和癌症特异性生存期相比,富尔曼分类法显示出独立的预测价值(p=0.0001)。新分类法中预测能力得以保持。在三类分级中,从I+II级变为III级时相对危险度(RR)为2.31(p=0.0001),从III级变为IV级时RR为2.47(p=0.0001);在两类分级中,从I+II级变为III+IV级时RR为2.8(p=0.001)。
我们的结果表明,将富尔曼分级分为三分级或两分级方案在无进展生存期和癌症特异性生存期方面具有相同的预测准确性。III级和IV级有不同的预后结果,因此三分级分类法似乎更适合描述这些患者的病程。